Gunderson Dettmer Advises Vir Biotechnology on $150 Million Public Offering of Common Stock

Client News
November 16, 2026

Gunderson Dettmer represented Vir Biotechnology, a clinical-stage biopharmaceutical company listed on Nasdaq under the symbol “VIR,” in a $150 million underwritten public offering of its common stock.

The offering closed on November 16, 2026. Leerink Partners, Morgan Stanley and Evercore ISI acted as bookrunning managers for the offering. Raymond James acted as co-manager for the offering.

The Gunderson deal team was led by Alexa Belonick and included Daniel Reichert, Hannah Pastore, Lydia Wang, Scott Paraker, and Jace Clegg.

Related People

Alexa Belonick
PARTNER
P +1 415 801 4940

Daniel Reichert
ASSOCIATE
P +1 650 463 5219

© 2026 Gunderson Dettmer; all rights reserved.

Hannah R. Pastore
ASSOCIATE
P +1 212 430 4250

Lydia D. Wang
ASSOCIATE
P +1 415 801 4866

Jace E. Clegg
PARTNER
P +1 646 490 9040

Related Services

Life Sciences

Public Companies/Public Offerings

Featured Insights

CLIENT NEWS

Gunderson Dettmer Advises Our Next Energy (ONE) on Business Combination with Wen Acquisition Corp

FIRM NEWS

Gunderson Dettmer Maintains Leadership in PitchBook League Tables Across Every Venture Financing Stage

CLIENT NEWS

Gunderson Dettmer Represents Guardant Health in $550 Million Convertible Senior Notes Offering

INSIGHTS

5 Veterans, 1 Question: The Best Lesson I Brought to My Legal Career

© 2026 Gunderson Dettmer; all rights reserved.

PUBLIC VENTURES

California Climate Disclosure Laws: Ninth Circuit Keeps SB-253 Scopes 1 and 2 Reporting in Effect; Holds Scope 3 Reporting and SB-261 Climate Risk Reporting Likely Unconstitutional

CLIENT NEWS

Clara Raises $105 Million in Equity and Growth Financing

CLIENT NEWS

Point72 Ventures Co-Leads Lumbra’s $25 Millon Series A

INSIGHTS

Client Insight: U.S. Outbound Investment Rules Under the COINS Act to be Expanded by Treasury Proposal

CLIENT NEWS

Gunderson Dettmer Advises Dialpad on Acquisition of Ada

CLIENT NEWS

Infisical Raises $40 Million Series B at $600 Million Valuation

FIRM NEWS

Gunderson Dettmer Named a Top 10 Investor Counsel in The Deal’s Q3 2026 PIPEs League Tables

INSIGHTS

WSJ Pro Venture Capital Interviews Gunderson Dettmer Partner Melissa Marks for “VCs Love Pro Rata Rights. Should They?”

© 2026 Gunderson Dettmer; all rights reserved.